Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Diabetes Care 29:1399-1401, 2006
DOI: 10.2337/dc06-0404
© 2006 by the American Diabetes Association
This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pietroiusti, A.
Right arrow Articles by Galante, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pietroiusti, A.
Right arrow Articles by Galante, A.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Pathophysiology/Complications
Brief Report

Cytotoxin-Associated Gene A Strains of Helicobacter Pylori Represent a Risk Factor for the Development of Microalbuminuria in Type 2 Diabetes

Antonio Pietroiusti, MD1, Maria Giuliano, MD2, Andrea Magrini, MD3, Antonio Bergamaschi, MD3 and Alberto Galante, MD1

1 Department of Internal Medicine, Tor Vergata University, Rome, Italy
2 Diabetologic Unit, S. Eugenio Hospital, Rome, Italy
3 Department of Biopathology–Occupational Medicine, Tor Vergata University, Rome, Italy

Address correspondence and reprint requests to Antonio Pietroiusti, MD, Department of Internal Medicine, Tor Vergata University, Via Montpellier 1, 00161 Rome, Italy. E-mail: pietroiusti{at}med.uniroma2.it

Abbreviations: CagA, cytotoxin-associated gene A • CRP, C-reactive protein


   INTRODUCTION
TOP
 INTRODUCTION
RESEARCH DESIGN AND METHODS
 RESULTS
 CONCLUSIONS
 References
 
The reasons why diabetic patients with microalbuminuria have marked endothelial damage (1,2) and an increased risk of atherosclerosis (3,4) are unclear. Infection with Helicobacter pylori, especially with strains carrying the cytotoxin-associated gene A (CagA), might represent a causal factor, since anti-CagA antibodies elicited by infection may cross-react with endothelial antigens (5), increasing the vascular damage associated with diabetes itself and consequent albumin leakage. Furthermore, infection might induce a persistent systemic inflammatory response, which is a recognized risk factor for atherosclerosis (6). In this study, we investigated the possible pathogenetic role of CagA-positive H. pylori strains in type 2 diabetic patients with microalbuminuria.


   RESEARCH DESIGN AND METHODS
TOP
 INTRODUCTION
 RESEARCH DESIGN AND METHODS
RESULTS
 CONCLUSIONS
 References
 
Consecutive ambulatory patients with a known history of type 2 diabetes who were ≥40 years of age were considered. Data on age, sex, BMI, smoking habit, history of hypertension or hyperlipidemia, disease duration, previous myocardial infarction, previous stroke, and HbA1c (A1C) were collected. Serum level of C-reactive protein (CRP), a marker of systemic inflammation, was measured only in patients without obvious inflammatory conditions. Exclusion criteria were presence of renal failure (creatinine >133 µmol/l), previous H. pylori eradication, and evidence of connective tissue, neoplastic, or hematological disease. Since virtually all peptic ulcers are due to H. pylori (7), and most of them to CagA-positive strains (8), a history of peptic ulcer would have implied in-practice "a priori" knowledge of infection, probably with CagA-positive strains. Thus, to avoid any bias in the selection of patients, we also decided to exclude patients with a history of peptic ulcer.

The investigation was performed according to the principles of the Declaration of Helsinky, written informed consent was obtained from all subjects, and the study was approved by the ethical committees of our institutions.

Urinary albumin excretion was measured with the use of nephelometry (Beckman Array System). Patients were classified as having normoalbuminuria if albumin excretion was <30 mg/24 h and as having microalbuminuria if it was 30–299 mg/24 h. Patients with macroalbuminuria (300 mg/24 h) were excluded. Serum IgG antibodies to H. pylori and to CagA protein were measured in duplicate by enyme-linked immunosorbent assay (Helori and CTX, respectively; Eurospital) according to the manufacturer’s instructions. The range of interassay variations for IgG to H. pylori and to CagA was 0–10% (median 7%). CRP was assessed by rate nephelometry (Behring NA latex CRP; Behring Institute) and, in samples with <0.25 mg/dl, by enzyme immunoassay (Imx Abbott Laboratories).

Data are presented as means ± SD. A two-tailed P value of <0.05 was considered statistically significant.

Univariate analysis and a multiple logistic regression, including factors possibly affecting the risk of microalbuminuria or the risk of H. pylori infection, were used to estimate the odds ratios (ORs) and 95% CIs for microalbuminuria associated with infection by H. pylori or by CagA-positive strains. Mann-Whitney U test was used when comparing CRP values. All analyses were performed with SPSS release 13 software.


   RESULTS
TOP
 INTRODUCTION
 RESEARCH DESIGN AND METHODS
 RESULTS
CONCLUSIONS
 References
 
Overall, 687 patients were screened for the study. However, 500 patients were actually included, since 187 did not meet inclusion criteria or refused participation. A total of 112 patients (22.4%) had microalbuminuria. They were older (59.9 ± 8.2 vs. 56.5 ± 11.8 years; P = 0.0006) and had a more frequent history of stroke (9.8 vs. 2.8%; OR 4.50 [95% CI 1.95–10.35]) or myocardial infarction (18.7 vs. 8.5%; 2.48 [1.37–4.49]) compared with normoalbuminuric patients. No significant difference was observed in other characteristics, such as male sex (62.5 vs. 57.7%), BMI (29.± 3.0 vs. 28.7 ± 3.1 kg/m2), smoking (38.3 vs. 39.4%), father’s manual job (53.3 vs. 53.6%), hypertension (60.7 vs. 51.0%), hyperlipidemia (10.7 vs. 9.3%), disease duration (7.8 ± 6.5 vs. 6.9 ± 6.4 years), and A1C (5.9 ± 1.2 vs. 5.8 ± 1.1%).

Anti–H. pylori IgGs were found in 73 (68%) patients with microalbuminuria and 224 (58%) normoalbuminuric patients (P = NS), whereas anti-CagA antibodies were detected in 44 (39%) patients with microalbuminuria and 56 (14%) patients with normoalbuminuria (OR 3.83 [95% CI 2.38–6.15], P < 0.0001). This significant difference persisted in a multivariate analysis (Table 1).


View this table:
[in this window]
[in a new window]
  		Table 1— ORs for CagA-positive H. pylori strains in microalbuminuric patients compared with normoalbuminuric patients after adjusting for possible confounding factors

 
CRP values were 2.07 ± 1.81 mg/dl in 157 patients with microalbuminuria and 0.88 ± 1.22 mg/dl in 66 normoalbuminuric patients (P < 0.0001). No significant difference in CRP values was detected between 20 CagA-positive subjects and 46 CagA-negative patients with microalbuminuria: 2.02 ± 1.89 vs. 2.1 ± 1.61 mg/dl.


   CONCLUSIONS
TOP
 INTRODUCTION
 RESEARCH DESIGN AND METHODS
 RESULTS
 CONCLUSIONS
References
 
This study shows that virulent strains of H. pylori are associated with microalbuminuria in type 2 diabetic patients. A cause-and-effect relationship may be plausible, since these strains have antigenic sequences common to endothelial cells (5), and the systemic immune response to the infection may cause immunomediated injury at the level of the endothelium, causing albumin leakage. Interestingly, these endothelial antigenic sequences are not exposed under normal conditions (5); therefore, endothelial damage associated with diabetes itself may cause their exposure, determining the vicious cycle of additional damage due to anti-CagA antibodies. The persistence of this mechanism may trigger the cascade of events leading to atherosclerosis, which has been found to be associated with CagA infection in several studies (9–18).

As shown in previous reports (19–21), we found an increase of CRP, a sensitive marker of systemic inflammation, in patients with microalbuminuria. We did not detect, however, an association between CRP and CagA infection. Therefore, although systemic inflammation probably plays a role in inducing atherosclerosis in patients with microalbuminuria, sources other than H. pylori infection are probably involved.

Our findings may be important for the prevention of microalbuminuria in type 2 diabetes. In fact, all strains of H. pylori may be eradicated by a short course of specific antibiotic therapy (22), and antibody response tends to disappear with time after eradication (23). Prospective studies are needed to confirm this hypothesis.

In conclusion, we found a strong association between infection with CagA-positive strains of H. pylori and microalbuminuria in type 2 diabetes. This association may explain the widespread endothelial damage and the high risk of atherosclerosis reported in these patients. This finding may open new perspectives for the prevention of this complication.


   Footnotes
 
A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received for publication February 21, 2006. Accepted for publication March 6, 2006.


   References
TOP
 INTRODUCTION
 RESEARCH DESIGN AND METHODS
 RESULTS
 CONCLUSIONS
 References
 

  1. Ritz E: Albuminuria and vascular damage-the vicious twins (Editorial). N Engl J Med 348:2349–2352, 2003[Free Full Text]
  2. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensent T, Kofoed-Enevoldsen A: Albuminuria reflects widespread vascular damage: the Steno hypothesis. Diabetologia 32:219–226, 1989[Medline]
  3. Agewall S, Wikstrand J, Ljungmans S, Fageberg B: Urinary albumin excretion is associated with the intima-media tickness of the carotid artery in hypertensive males with non insulin dependent diabetes mellitus. J Hypertens 13:463–469, 1995[Medline]
  4. Gall MA, Borch-Johnsen K, Hougaard P, Nielsen FS, Parving HH: Albuminuria and poor glycemic control predict mortality in NIDDM. Diabetes 44:1303–1309, 1995[Abstract]
  5. Franceschi F, Sepulveda AR, Gasbarrini A, Pola P, Silveri N, Gasbarrini G, Graham DY, Genta RM: Cross-reactivity of anti-CagA antibodies with vascular wall antigens: possible pathogenic link between Helicobacter pylori infection and atherosclerosis. Circulation 106:430–434, 2002[Abstract/Free Full Text]
  6. Ross R: Atherosclerosis: an inflammatory disease. N Engl J Med 340:115–126, 1999[Free Full Text]
  7. O’Connor HJ: The role of Helicobacter pylori in peptic ulcer disease. Scand J Gastroenterol 29 (Suppl. 201):11–15, 1994
  8. Censini S, Lange C, Xiang Z, Crabtree JE, Ghiara P, Borodovsky M, Rappuoli R, Covacci A: Cag, a pathogenicity island of Helicobacter pylori, encodes type I specific and disease-associated virulence factors. Proc Natl Acad Sci 93:14648–14653, 1996[Abstract/Free Full Text]
  9. Pietroiusti A, Diomedi M, Silvestrini M, Cupini LM, Luzzi I, Gomez-Miguel MJ, Bergamaschi A, Magrini A, Carrabs T, Vellini M, Galante A: Cytotoxin-associated gene-A-positive Helicobacter pylori strains are associated with atherosclerotic stroke. Circulation 106:580–584, 2002[Abstract/Free Full Text]
  10. Pasceri V, Cammarota G, Patti G, Cuoco L, Gasbarrini A, Grillo RL, Fedeli G, Gasbarrini G, Maseri A: Association of virulent Helicobacter pylori strains with ischaemic heart disease. Circulation 97:1675–1679, 1998[Abstract/Free Full Text]
  11. Gabrielli M, Santoliquido A, Cremonini F, Cicconi V, Candelli M, Serricchio M, Tondi P, Pola R, Gasbarrini G, Pola P, Gasbarrini A: CagA-positive cytotoxic H. pylori strains as a link between plaque instability and atherosclerotic stroke. Eur Heart J 25:64–68, 2004[Abstract/Free Full Text]
  12. Gunn M, Stephens JC, Thompson JR, Rathbone BJ, Samani NJ: Significant association of cagA positive Helicobacter pylori strains with risk of premature myocardial infarction. Heart 84:267–271, 2000[Abstract/Free Full Text]
  13. Singh RK, McMahon AD, Patel H, Packard CJ, Rathbone BJ, Samani NJ: Prospective analysis of the association of infection with CagA bearing strains of Helicobacter pylori and coronary heart disease. Heart 88:43–46, 2002[Abstract/Free Full Text]
  14. Figura N, Palazzuoli A, Faglia S, Lenzi C, Borrello F, Palazzuoli V, Nami R, Dal Canto N, De Regis F, Vaira D, Gennari L, Giordano N, Gennari C: Infection by CagA-positive Helicobacter pylori strains in patients with ischemic heart disease: prevalence and association with exercise-induced electrocardiographic abnormalities. Dig Dis Sci 47:831–836, 2002[Medline]
  15. Preusch MR, Grau AJ, Buggle F, Lichy C, Bartel J, Black C, Rudi J: Association between cerebral ischemia and cytotoxin-associated gene-A bearing strains of Helicobacter pylori. Stroke 35:1800–1804, 2004[Abstract/Free Full Text]
  16. Mayr M, Kiechl S, Mendall MA, Willeit J, Wick G, Xu Q: Increased risk of atherosclerosis is confined to CagA-positive Helicobacter pylori strains: prospective results from the Bruneck study. Stroke 34:610–615, 2003[Abstract/Free Full Text]
  17. Diomedi M, Pietroiusti A, Silvestrini M, Rizzato B, Cupini LM, Ferrante F, Magrini A, Bergamaschi A, Galante A, Bernardi G: CagA-positive Helicobacter pylori strains may influence the natural history of atherosclerotic stroke. Neurology 63:800–804, 2004[Abstract/Free Full Text]
  18. Shmuely H, Passaro DJ, Vaturi M, Sagie A, Pitlik S, Samra Z, Niv Y, Koren R, Harell D, Yahav J: Association of CagA+ Helicobacter pylori with aortic atheroma. Atherosclerosis 179:127–132, 2005[Medline]
  19. Festa A, D’Agostino R, Howard G, Mykkanen L, Tracy R, Haffner S: Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: the Insulin Resistance Atherosclerosis study. Kidney Int 58:1703–1710, 2000[Medline]
  20. Stuveling EM, Bakker JL, Hillege HL, Burgerhof JG, de Long PE, Gans RO, de Zeeuw D, the PREVEND Study Group: C-reactive protein modifies the relationship between blood pressure and microalbuminuria. Hypertension 43:791–796, 2004[Abstract/Free Full Text]
  21. Gomes MB, Nogueira VG: Acute phase proteins and microalbuminuria among patients with type 2 diabetes. Diabetes Res Clin Pract 66:31–39, 2004[Medline]
  22. Bytzer B, O’Morain C: Treatment of Helicobacter pylori. Helicobacter 10 (Suppl. 1):40–46, 2005
  23. Cutler AF, Vajravel M: Long term follow-up of Helicobacter pylori serology after successful eradication. Am J Gastroenterol 91:85–88, 1996[Medline]

Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?



This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pietroiusti, A.
Right arrow Articles by Galante, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pietroiusti, A.
Right arrow Articles by Galante, A.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum